Company News

Kelun-Biotech's TROP2 ADC Sacituzumab Tirumotecan (sac-TMT) is approved for marketing in its second indication of EGFRm NSCLC by the NMPA.

Study Results Abstracts for Kelun-Biotech’s TROP2 ADC Sacituzumab Tirumotecan (sac-TMT) will be presented at 2025 ASCO Genitourinary Cancers Symposium held in San Francisco from February 13-15, 2025.

Kelun-Biotech’s biosimilar product Cetuximab N01 Injection (达泰莱®, formerly A140) was approved for marketing by NMPA of China.

Kelun-Biotech’s tagitanlimab approved for marketing for second indication in combination with cisplatin and gemcitabine for the first-line treatment of patients with recurrent or metastatic NPC.

Kelun-Biotech's innovative ADC SKB445 receives IND approval from NMPA in China.

The second NDA for Kelun-Biotech's innovative HER2 ADC (trastuzumab botidotin) was formally accepted by the NMPA in China.

Kelun-Biotech's Anti-PD-L1 (Tagitanlimab, 科泰莱®) approved for marketing by NMPA of China for 3L+ nasopharyngeal carcinoma.

Kelun-Biotech’s TROP2 ADC Sacituzumab tirumotecan (sac-TMT, 佳泰莱®) approved for marketing by NMPA of China for 2L+ advanced or metastatic TNBC.

Kelun-Biotech’s TROP2-ADC SKB264 (sac-TMT) Third NDA Accepted by NMPA for locally advanced or metastatic EGFR-mutant NSCLC.

Multiple Study Results of Kelun-Biotech’s TROP2-ADC SKB264 (sac-TMT) were presented at 2024 CSCO Congress.

Positive results from multiple studies of Kelun Biotech's TROP2 ADC (Sac-TMT) in advanced solid tumors were presented at 2024 ESMO Congress.

Three study abstracts for sac-TMT (TROP2 ADC) to be presented at 2024 ESMO Congress.